Takeda Reports Positive Phase 3 Results for Arcotatug Tavatecan
Takeda said the G-HOPE-001 study showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival in previously treated advanced gastric or gastroesophageal junction cancer.
Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA…